| Objective:To investigate the clinical effect of sacubitril-valsartan in the treatment of patients with heart failure after emergency percutaneous coronary intervention(PCI)for acute myocardial infarction(AMI)and its influence on the prognosis of patients,To provide some diagnosis and treatment ideas for improving the prognosis of patients with heart failure after PCI for acute myocardial infarction.Methods: Sixty patients with acute myocardial infarction complicated with heart failure after emergency PCI from January 2020 to June 2021 in the Department of Cardiology,The PLA 968 th Hospital and the Jinzhou Central Hospitalwere selected as the study subjects.All patients were randomly divided into the control group and the test group.Patients in the control group underwent routine heart failure treatment.Patients in the observation group were replaced with the ACEI/ARB group as sacurubatrasarsone.Subsequently,the clinical data and laboratory test data of the two groups were observed and recorded during the subsequent treatment,and these patients were followed up at 2 months,4 months and 6 months after operation.The collected data during follow-up and the clinical data of the patients were analyzed to compare the changes of cardiac color ultrasound related indicators before and after receiving the corresponding treatment between the control group(enalapril group)and the test group(sacubitril-valsartan group).At the same time,the various cardiovascular adverse events and readmission rates due by cardiovascular events occurred within 6 months of follow-up after PCI in the control group(enalapril group)and the test group(sacubitril-valsartan group)were statistically analyzed and compared.Result: The NT-pro BNP and LVEDD levels at 6 months after treatment in the test group(sacubitril-valsartan group)were significantly lower than those in the control group(enalapril group),while the LVEF levels in the test group(sacubitril-valsartan group)were significantly higher than those in the control group(enalapril group),the KCCQ scale(KCCQ)scores were higher than those in the control group(enalapril group),and statistical analysis revealed statistically significant differences(P< 0.05);There was significant difference between the control group(enalapril group)and the test group(sacubitril-valsartan group)(P > 0.05).Conclusion:Sacubitril-valsartan is more effective than enalapril in improving cardiac function in patients with heart failure after emergency PCI for acute myocardial infarction.It can significantly reduce the patient readmission rate. |
PDF Full Text Request